WO2024044633A3 - Oxytocin derivatives and methods of use - Google Patents

Oxytocin derivatives and methods of use Download PDF

Info

Publication number
WO2024044633A3
WO2024044633A3 PCT/US2023/072729 US2023072729W WO2024044633A3 WO 2024044633 A3 WO2024044633 A3 WO 2024044633A3 US 2023072729 W US2023072729 W US 2023072729W WO 2024044633 A3 WO2024044633 A3 WO 2024044633A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
oxytocin
compounds
oxytocin derivatives
disclosure
Prior art date
Application number
PCT/US2023/072729
Other languages
French (fr)
Other versions
WO2024044633A2 (en
Inventor
Alex Kiselyov
Christian L. ROTH
Clinton T. ELFERS
Original Assignee
Seattle Children's Hospital (D/B/A Seattle Children's Research Institute)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) filed Critical Seattle Children's Hospital (D/B/A Seattle Children's Research Institute)
Publication of WO2024044633A2 publication Critical patent/WO2024044633A2/en
Publication of WO2024044633A3 publication Critical patent/WO2024044633A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Provided herein are compounds of formula (I). In certain embodiments, the compounds of the disclosure are analogs of oxytocin. In certain embodiments, the compounds of the disclosure have significantly larger half-lives than oxytocin, and are useful in the treatment of obesity and in the reduction of appetite or food intake in a subject.
PCT/US2023/072729 2022-08-23 2023-08-23 Oxytocin derivatives and methods of use WO2024044633A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263373280P 2022-08-23 2022-08-23
US63/373,280 2022-08-23

Publications (2)

Publication Number Publication Date
WO2024044633A2 WO2024044633A2 (en) 2024-02-29
WO2024044633A3 true WO2024044633A3 (en) 2024-04-04

Family

ID=90014186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072729 WO2024044633A2 (en) 2022-08-23 2023-08-23 Oxytocin derivatives and methods of use

Country Status (1)

Country Link
WO (1) WO2024044633A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235956A1 (en) * 2000-01-11 2004-11-25 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20110044905A1 (en) * 2008-03-31 2011-02-24 Ferring B.V. Oxytocin analogues
US20170081368A1 (en) * 2014-06-06 2017-03-23 Hoffmann-La Roche Inc. Peptides as oxytocin agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235956A1 (en) * 2000-01-11 2004-11-25 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US20110044905A1 (en) * 2008-03-31 2011-02-24 Ferring B.V. Oxytocin analogues
US20170081368A1 (en) * 2014-06-06 2017-03-23 Hoffmann-La Roche Inc. Peptides as oxytocin agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINTON T. ELFERS: "Novel Long-Acting Oxytocin Analog with Increased Efficacy in Reducing Food Intake and Body Weight", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI), BASEL, CH, vol. 23, no. 19, Basel, CH , pages 11249, XP093158889, ISSN: 1422-0067, DOI: 10.3390/ijms231911249 *
CLINTON T. ELFERS: "Robust Reductions of Body Weight and Food Intake by an Oxytocin Analog in Rats", FRONTIERS IN PHYSIOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 12, 27 September 2021 (2021-09-27), CH , XP093158887, ISSN: 1664-042X, DOI: 10.3389/fphys.2021.726411 *

Also Published As

Publication number Publication date
WO2024044633A2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2003103603A3 (en) Novel formate salt of o-desmethyl-venlafaxine
NO20055649L (en) Substituted dihydroquinazoline with antivial properties
MXPA05012323A (en) Cyclic sulfonamides for inhibition of gamma-secretase.
RS50603B (en) Pyridin-4-yl-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
GEP20094826B (en) 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands
UA83233C2 (en) Substituted 2-aminotetralin for the treatment of depression
CA3156303A1 (en) 5-fluoronicotinamide derivatives and uses thereof
NO20082144L (en) Mixture of iron and copper salts that mask metallic taste
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
WO2005044192A3 (en) Triazole compounds and uses related thereto
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.
GB0321003D0 (en) Compounds, compositions and uses
DE60232173D1 (en) USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF ADIPOSITAS OR TO REDUCE FOOD RECEPTION
WO2024044633A3 (en) Oxytocin derivatives and methods of use
EP1532131A4 (en) Motilide compounds
MXPA06004308A (en) Isopentyl carboxanilides for combating undesired micro-organisms.
CA2501321A1 (en) Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
WO2005020887A3 (en) Method for treatment of severe acute respiratory syndrome
TNSN05248A1 (en) Crystalline n-formyl hydroxylamine compounds
WO2004037166A3 (en) Therapeutic guanidines
WO2021015294A3 (en) Combination therapy for cancer treatment
AU2003288739A1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause